{"id":55050,"date":"2026-01-22T09:23:24","date_gmt":"2026-01-22T01:23:24","guid":{"rendered":"https:\/\/flcube.com\/?p=55050"},"modified":"2026-01-22T09:23:25","modified_gmt":"2026-01-22T01:23:25","slug":"gsk-acquires-rapt-therapeutics-for-2-2-billion-adding-ozureprubart-for-food-allergy-protection","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55050","title":{"rendered":"GSK Acquires RAPT Therapeutics for $2.2\u202fBillion, Adding Ozureprubart for Food Allergy Protection"},"content":{"rendered":"\n<p><strong>GlaxoSmithKline plc<\/strong> (GSK, <a href=\"https:\/\/www.google.com\/finance\/quote\/GSK:NYSE\">NYSE:\u202fGSK<\/a>) announced a definitive agreement to acquire <strong>RAPT Therapeutics<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/RAPT:NASDAQ\">NASDAQ:\u202fRAPT<\/a>) for <strong>USD\u202f58.00 per share<\/strong>, representing an aggregate equity value of <strong>$2.2\u202fbillion<\/strong> and a net upfront investment of <strong>$1.9\u202fbillion<\/strong>. The acquisition grants GSK <strong>global rights to ozureprubart<\/strong> (excluding Greater China), a <strong>long\u2011acting anti\u2011IgE monoclonal antibody<\/strong> in Phase\u202f2b development for <strong>prophylactic protection against food allergens<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquirer<\/strong><\/td><td>GlaxoSmithKline plc (NYSE:\u202fGSK)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>RAPT Therapeutics (NASDAQ:\u202fRAPT)<\/td><\/tr><tr><td><strong>Purchase Price<\/strong><\/td><td>USD\u202f58.00 per share<\/td><\/tr><tr><td><strong>Equity Value<\/strong><\/td><td>USD\u202f2.2\u202fbillion<\/td><\/tr><tr><td><strong>Net Investment<\/strong><\/td><td>USD\u202f1.9\u202fbillion (net of cash acquired)<\/td><\/tr><tr><td><strong>Expected Close<\/strong><\/td><td>Q1\u202f2026<\/td><\/tr><tr><td><strong>Key Asset<\/strong><\/td><td>Ozureprubart (long\u2011acting anti\u2011IgE mAb)<\/td><\/tr><tr><td><strong>Rights Acquired<\/strong><\/td><td>Global rights excluding Greater China (owned by Jemincare)<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Phase\u202f2b (prestIgE trial)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Prophylactic protection against food allergens<\/td><\/tr><tr><td><strong>Phase\u202f2b Data<\/strong><\/td><td>Expected 2027<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> <strong>Anti\u2011immunoglobulin E (IgE) monoclonal antibody<\/strong> that <strong>neutralizes IgE<\/strong>, preventing allergic cascade triggered by food allergens<\/li>\n\n\n\n<li><strong>Long\u2011Acting:<\/strong> Designed for <strong>extended duration<\/strong> vs. short\u2011acting anti\u2011IgE therapies (e.g., omalizumab)<\/li>\n\n\n\n<li><strong>Clinical Development:<\/strong><\/li>\n\n\n\n<li><strong>Phase\u202f2b (prestIgE)<\/strong> \u2013 Monotherapy for <strong>at\u2011risk adult and pediatric populations<\/strong><\/li>\n\n\n\n<li><strong>Phase\u202f3 planned<\/strong> \u2013 to expand across <strong>food allergy indications<\/strong> (peanut, milk, egg)<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Potential <strong>first\u2011in\u2011class long\u2011acting prophylactic<\/strong> for food allergies vs. <strong>oral immunotherapy<\/strong> (Aimmune, DBV)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-competitive-landscape\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Food Allergy Market<\/th><th>Anti\u2011IgE Market<\/th><\/tr><\/thead><tbody><tr><td><strong>Food Allergy Prevalence (US)<\/strong><\/td><td>8% children, 11% adults<\/td><td>\u2013<\/td><\/tr><tr><td><strong>Severe\/Requiring Prophylaxis<\/strong><\/td><td>1.6\u202fmillion (US)<\/td><td>\u2013<\/td><\/tr><tr><td><strong>Current Standard<\/strong><\/td><td>Epinephrine (reactive), oral immunotherapy (partial efficacy)<\/td><td><\/td><\/tr><tr><td><strong>Omalizumab Sales (2025)<\/strong><\/td><td>\u2013<\/td><td>$3.8\u202fbillion (Xolair)<\/td><\/tr><tr><td><strong>Prophylactic Anti\u2011IgE Market (2030E)<\/strong><\/td><td>$4.5\u202fbillion<\/td><td>\u2013<\/td><\/tr><tr><td>**Ozureprubart Peak Share<\/td><td>12%<\/td><td>\u2013<\/td><\/tr><tr><td><strong>Peak Revenue (2032E)<\/strong><\/td><td>$540\u202fmillion<\/td><td>\u2013<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Key Competitors:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Omalizumab<\/strong> (Roche\/Novartis) \u2013 Short\u2011acting anti\u2011IgE, approved for asthma\/food allergy off\u2011label<\/li>\n\n\n\n<li><strong>Ligelizumab<\/strong> (Novartis) \u2013 Next\u2011gen anti\u2011IgE, Phase\u202fIII for food allergy<\/li>\n\n\n\n<li><strong>Oral Immunotherapy:<\/strong> Palforzia (Aimmune\/Nestl\u00e9) \u2013 Peanut OIT, limited efficacy and safety concerns<\/li>\n\n\n\n<li><strong>Ozureprubart<\/strong> \u2013 <strong>Long\u2011acting prophylactic<\/strong> with <strong>potential for monthly\u2011quarterly dosing<\/strong>, avoiding daily OIT burden<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning\">Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>For GSK:<\/strong><\/li>\n\n\n\n<li><strong>Complements allergy franchise<\/strong> (Nucala, Xolair) with <strong>first\u2011in\u2011class food allergy prophylactic<\/strong><\/li>\n\n\n\n<li><strong>Leverages GSK\u2019s commercial footprint<\/strong> in allergy\/immunology (12,000 US prescribers)<\/li>\n\n\n\n<li><strong>Platform potential:<\/strong> Anti\u2011IgE technology applicable to <strong>asthma, chronic urticaria, and other allergic diseases<\/strong><\/li>\n\n\n\n<li><strong>Manufacturing:<\/strong> RAPT\u2019s <strong>Hayward, CA facility<\/strong> will be integrated into GSK\u2019s biologics network; <strong>scale\u2011up<\/strong> for Phase\u202f3 planned 2027<\/li>\n\n\n\n<li><strong>Regulatory Path:<\/strong> <strong>BTD<\/strong> expected after Phase\u202f2b data; <strong>PDUFA target<\/strong> <strong>2029<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding transaction completion, clinical development timelines, and commercial forecasts for ozureprubart. Actual results may differ due to clinical trial outcomes, competitive responses, and regulatory approval processes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>GlaxoSmithKline plc (GSK, NYSE:\u202fGSK) announced a definitive agreement to acquire RAPT Therapeutics (NASDAQ:\u202fRAPT) for USD\u202f58.00&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[278,184,2922,914,2921],"class_list":["post-55050","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-glaxosmithkline","tag-gsk","tag-nasdaq-rapt","tag-nyse-gsk","tag-rapt-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>GSK Acquires RAPT Therapeutics for $2.2\u202fBillion, Adding Ozureprubart for Food Allergy Protection - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"GlaxoSmithKline plc (GSK, NYSE:\u202fGSK) announced a definitive agreement to acquire RAPT Therapeutics (NASDAQ:\u202fRAPT) for USD\u202f58.00 per share, representing an aggregate equity value of $2.2\u202fbillion and a net upfront investment of $1.9\u202fbillion. The acquisition grants GSK global rights to ozureprubart (excluding Greater China), a long\u2011acting anti\u2011IgE monoclonal antibody in Phase\u202f2b development for prophylactic protection against food allergens.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55050\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GSK Acquires RAPT Therapeutics for $2.2\u202fBillion, Adding Ozureprubart for Food Allergy Protection\" \/>\n<meta property=\"og:description\" content=\"GlaxoSmithKline plc (GSK, NYSE:\u202fGSK) announced a definitive agreement to acquire RAPT Therapeutics (NASDAQ:\u202fRAPT) for USD\u202f58.00 per share, representing an aggregate equity value of $2.2\u202fbillion and a net upfront investment of $1.9\u202fbillion. The acquisition grants GSK global rights to ozureprubart (excluding Greater China), a long\u2011acting anti\u2011IgE monoclonal antibody in Phase\u202f2b development for prophylactic protection against food allergens.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55050\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-22T01:23:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-22T01:23:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55050#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55050\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GSK Acquires RAPT Therapeutics for $2.2\u202fBillion, Adding Ozureprubart for Food Allergy Protection\",\"datePublished\":\"2026-01-22T01:23:24+00:00\",\"dateModified\":\"2026-01-22T01:23:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55050\"},\"wordCount\":426,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"GlaxoSmithKline\",\"GSK\",\"NASDAQ: RAPT\",\"NYSE: GSK\",\"RAPT Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55050#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55050\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55050\",\"name\":\"GSK Acquires RAPT Therapeutics for $2.2\u202fBillion, Adding Ozureprubart for Food Allergy Protection - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-22T01:23:24+00:00\",\"dateModified\":\"2026-01-22T01:23:25+00:00\",\"description\":\"GlaxoSmithKline plc (GSK, NYSE:\u202fGSK) announced a definitive agreement to acquire RAPT Therapeutics (NASDAQ:\u202fRAPT) for USD\u202f58.00 per share, representing an aggregate equity value of $2.2\u202fbillion and a net upfront investment of $1.9\u202fbillion. The acquisition grants GSK global rights to ozureprubart (excluding Greater China), a long\u2011acting anti\u2011IgE monoclonal antibody in Phase\u202f2b development for prophylactic protection against food allergens.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55050#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55050\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55050#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GSK Acquires RAPT Therapeutics for $2.2\u202fBillion, Adding Ozureprubart for Food Allergy Protection\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GSK Acquires RAPT Therapeutics for $2.2\u202fBillion, Adding Ozureprubart for Food Allergy Protection - Insight, China&#039;s Pharmaceutical Industry","description":"GlaxoSmithKline plc (GSK, NYSE:\u202fGSK) announced a definitive agreement to acquire RAPT Therapeutics (NASDAQ:\u202fRAPT) for USD\u202f58.00 per share, representing an aggregate equity value of $2.2\u202fbillion and a net upfront investment of $1.9\u202fbillion. The acquisition grants GSK global rights to ozureprubart (excluding Greater China), a long\u2011acting anti\u2011IgE monoclonal antibody in Phase\u202f2b development for prophylactic protection against food allergens.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55050","og_locale":"en_US","og_type":"article","og_title":"GSK Acquires RAPT Therapeutics for $2.2\u202fBillion, Adding Ozureprubart for Food Allergy Protection","og_description":"GlaxoSmithKline plc (GSK, NYSE:\u202fGSK) announced a definitive agreement to acquire RAPT Therapeutics (NASDAQ:\u202fRAPT) for USD\u202f58.00 per share, representing an aggregate equity value of $2.2\u202fbillion and a net upfront investment of $1.9\u202fbillion. The acquisition grants GSK global rights to ozureprubart (excluding Greater China), a long\u2011acting anti\u2011IgE monoclonal antibody in Phase\u202f2b development for prophylactic protection against food allergens.","og_url":"https:\/\/flcube.com\/?p=55050","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-22T01:23:24+00:00","article_modified_time":"2026-01-22T01:23:25+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55050#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55050"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GSK Acquires RAPT Therapeutics for $2.2\u202fBillion, Adding Ozureprubart for Food Allergy Protection","datePublished":"2026-01-22T01:23:24+00:00","dateModified":"2026-01-22T01:23:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55050"},"wordCount":426,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["GlaxoSmithKline","GSK","NASDAQ: RAPT","NYSE: GSK","RAPT Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55050#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55050","url":"https:\/\/flcube.com\/?p=55050","name":"GSK Acquires RAPT Therapeutics for $2.2\u202fBillion, Adding Ozureprubart for Food Allergy Protection - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-22T01:23:24+00:00","dateModified":"2026-01-22T01:23:25+00:00","description":"GlaxoSmithKline plc (GSK, NYSE:\u202fGSK) announced a definitive agreement to acquire RAPT Therapeutics (NASDAQ:\u202fRAPT) for USD\u202f58.00 per share, representing an aggregate equity value of $2.2\u202fbillion and a net upfront investment of $1.9\u202fbillion. The acquisition grants GSK global rights to ozureprubart (excluding Greater China), a long\u2011acting anti\u2011IgE monoclonal antibody in Phase\u202f2b development for prophylactic protection against food allergens.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55050#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55050"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55050#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GSK Acquires RAPT Therapeutics for $2.2\u202fBillion, Adding Ozureprubart for Food Allergy Protection"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55050","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55050"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55050\/revisions"}],"predecessor-version":[{"id":55087,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55050\/revisions\/55087"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55050"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55050"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55050"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}